Fig. 1: Effects of sotorasib/fulzerasib combined with cetuximab in KRAS G12C mutant cell lines. | Cell Death Discovery

Fig. 1: Effects of sotorasib/fulzerasib combined with cetuximab in KRAS G12C mutant cell lines.

From: Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells

Fig. 1: Effects of sotorasib/fulzerasib combined with cetuximab in KRAS G12C mutant cell lines.The alternative text for this image may have been generated using AI.

Data was obtained at 72 h by MTT. Culture medium consisted of RPMI + 0.5% HS with 10 ng/ml of hEGF, except for H2122, which was cultured with 2% HS supplemented with hEGF. A Sotorasib + Cetuximab B Fulzerasib + Cetuximab. Values shown are means ± SD, represented with a horizontal bar, from three independent experiments. Data was analyzed by Chou–Talalay method, indicating CI < 1 synergy, CI = 1 additivity, and CI > 1 antagonism. Drug combination inhibition matrix of sotorasib (left), fulzerasib (right) and their combination with cetuximab on C H358, D H23 and E H2030 cultured in RPMI + 0.5% HS with 10 ng/ml of hEGF. The first row represents inhibition of cell proliferation in combination of fulzerasib/sotorasib at different doses with cetuximab (50 µg/mL), the second row shows inhibition of cell proliferation on a single agent of fulzerasib/sotorasib. The intensity of the red color increases with greater inhibition of cell proliferation. Values shown are means of three independent experiments.

Back to article page